Overview
Hypomagnesemia with secondary hypocalcemia occurs when low magnesium levels impair parathyroid hormone function, leading to decreased calcium absorption and hypocalcemia. This condition can result from various factors, including certain drug therapies, particularly proton pump inhibitors (PPIs) and other medications 145.Diagnosis
Key Diagnostic Criteria: Low serum magnesium levels (typically <0.75 mmol/L) and hypocalcemia (serum calcium <8.8 mg/dL) 1.
Recommended Tests: Serum magnesium and calcium levels, ionized calcium measurement 1.
Grading: Severity can be graded based on magnesium levels: mild (0.75-0.85 mmol/L), moderate (0.6-0.75 mmol/L), severe (<0.6 mmol/L) 1.Management
First-Line Treatments: Oral magnesium supplementation (e.g., magnesium oxide, chloride) 2.
Adjunctive Treatments: Intravenous magnesium for severe cases or when rapid correction is needed 2.
Calcium Supplementation: To address secondary hypocalcemia, particularly in symptomatic patients 1.
Drug Review: Evaluate and potentially discontinue or adjust medications known to cause hypomagnesemia (e.g., PPIs) 145.Special Populations
Pediatrics: Magnesium replacement should be carefully administered via appropriate routes and doses to treat emergencies like torsades de pointe 2.
Elderly: Higher risk due to polypharmacy; monitor magnesium levels regularly, especially in those on multiple medications including PPIs 4.
Comorbidities: Patients with renal impairment may require adjusted dosing of magnesium supplements 1.Key Recommendations
Monitor magnesium levels in patients on PPIs and other risk medications, especially in elderly and those with polypharmacy (Evidence: Moderate 45).
Initiate magnesium supplementation for confirmed hypomagnesemia, adjusting based on severity and clinical response (Evidence: Moderate 2).
Consider calcium supplementation concurrently to manage secondary hypocalcemia (Evidence: Moderate 1).
Review and adjust medication regimens to minimize risk factors for hypomagnesemia (Evidence: Expert opinion 1).References
1 Xiao Y, Fang J, Zhou Y, Zhou T. Detection and warning of drug-induced hypomagnesemia: a pharmacovigilance study of the FDA Adverse Event Reporting System. Magnesium research 2024. link
2 Anderson S, Farrington E. Magnesium Treatment in Pediatric Patients. Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners 2021. link
3 Puchalski AR, Hodge MB. Parathyroid hormone resistance from severe hypomagnesaemia caused by cisplatin. Endokrynologia Polska 2020. link
4 van Orten-Luiten ACB, Janse A, Verspoor E, Brouwer-Brolsma EM, Witkamp RF. Drug use is associated with lower plasma magnesium levels in geriatric outpatients; possible clinical relevance. Clinical nutrition (Edinburgh, Scotland) 2019. link
5 Danziger J, William JH, Scott DJ, Lee J, Lehman LW, Mark RG et al.. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney international 2013. link